WO2012053667A1 - USE OF β-GLUCAN DELAYING THE BIOSYNTHESIS OF YEAST AND MOLD UNDER ANAEROBIC CONDITION - Google Patents
USE OF β-GLUCAN DELAYING THE BIOSYNTHESIS OF YEAST AND MOLD UNDER ANAEROBIC CONDITION Download PDFInfo
- Publication number
- WO2012053667A1 WO2012053667A1 PCT/KP2011/000023 KP2011000023W WO2012053667A1 WO 2012053667 A1 WO2012053667 A1 WO 2012053667A1 KP 2011000023 W KP2011000023 W KP 2011000023W WO 2012053667 A1 WO2012053667 A1 WO 2012053667A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- glucan
- control group
- change
- yeast
- Prior art date
Links
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title claims abstract description 51
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 51
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 23
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 20
- 235000021109 kimchi Nutrition 0.000 claims abstract description 21
- 208000006454 hepatitis Diseases 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 3
- 235000013402 health food Nutrition 0.000 claims abstract 2
- 235000011194 food seasoning agent Nutrition 0.000 claims description 8
- 235000013311 vegetables Nutrition 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 57
- 230000008859 change Effects 0.000 description 48
- 210000004369 blood Anatomy 0.000 description 46
- 239000008280 blood Substances 0.000 description 46
- 238000012360 testing method Methods 0.000 description 41
- 208000024891 symptom Diseases 0.000 description 39
- 210000002966 serum Anatomy 0.000 description 33
- 210000004185 liver Anatomy 0.000 description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 29
- 239000003814 drug Substances 0.000 description 29
- 239000008103 glucose Substances 0.000 description 29
- 238000000034 method Methods 0.000 description 27
- 229940079593 drug Drugs 0.000 description 26
- 230000006872 improvement Effects 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 15
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 229920001282 polysaccharide Polymers 0.000 description 13
- 239000005017 polysaccharide Substances 0.000 description 13
- 150000004804 polysaccharides Chemical class 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000005259 measurement Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 235000019625 fat content Nutrition 0.000 description 8
- 102000007562 Serum Albumin Human genes 0.000 description 7
- 108010071390 Serum Albumin Proteins 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- 241001662043 Icterus Species 0.000 description 5
- 206010023126 Jaundice Diseases 0.000 description 5
- 102000003929 Transaminases Human genes 0.000 description 5
- 108090000340 Transaminases Proteins 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 230000007102 metabolic function Effects 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 231100000816 toxic dose Toxicity 0.000 description 5
- 239000013585 weight reducing agent Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000000225 effect on diabetes Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000036252 glycation Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000036228 toxication Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241001582888 Lobus Species 0.000 description 2
- 240000001439 Opuntia Species 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003809 bile pigment Substances 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 244000257727 Allium fistulosum Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 241001480003 Chaetothyriales Species 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- -1 carboxylethylglucan Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000332 continued effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000081 effect on glucose Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/20—Products from fruits or vegetables; Preparation or treatment thereof by pickling, e.g. sauerkraut or pickles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/271—Curdlan; beta-1-3 glucan; Polysaccharides produced by agrobacterium or alcaligenes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention relates to the use of ⁇ -glucan having the immune and hyperhepatia activity of the body. Background and purpose of Invention
- ⁇ -Glucan the main component of mushroom polysaccharide is being watched and the research of its structure, mechanism of the action and its use has achieved the great progress, and some of them are widely disseminated in the field of medical treatment for the promotion of health.
- ⁇ -Glucan is a kind of functional polysaccharide from vegetable derivation and included in barley, black yeast, or mushroom and it is examined to decreasing the cholesterol content in the blood or restraining elevation of blood glucose value, treating of the adipositas, anticancer effectiveness, treating effectiveness of hepatic diseases.
- WO2000003608 A l 20000127 disclosed a pulverized Kimchi seasoning composition and it's preparing method and WO2001084942 disclosed the preparing method of Kimchi with silkworm Dong-Chung-Ha-Cho.
- This Kimchi is beneficial to the health of the body owing to its containging Cordyceps mil itaris, has a good flavour.
- WO200 I 087078 A I 2001 1 122 disclosed white Kimchi containg opuntia, which is beneficial to the health of the body owing to its containing opuntia and has a peculiar flavour, thereby becoming a globalized food.
- This invention relates to the use of ⁇ -Glucan delaying the biosynthesis process of yeast and mold in anaerobic condition and provides the methods to apply ⁇ -Glucan to vegetable-fermented foodstuffs such as Kimchi.
- this invention provides the methods to apply ⁇ -Gl ucan delaying the biosynthesis process of yeast and mold under anaerobic condition to treatment of the disease such as hepatic diseases and adipositas.
- ⁇ -Glucan delays selectively only the growth of yeast and mold in anaerobic condition and increases the biosynthesis of B
- This invention discloses the method of using of ⁇ -Glucan in the fermented foodstuffs such as imchi and unrefined liquor.
- ⁇ -Glucan in the fermented foodstuffs such as imchi and unrefined liquor.
- 5g of ⁇ -Glucan can be mixed in its seasoning. With this usage, Kimchi was tasty and the period to be not sour was extended than comparison.
- This invention describes the method of using of ⁇ -Glucan in treating of modern diseases such as adipositas and diabetes and hepatic disease.
- ⁇ -Glucan in indices related to all examination enumerated has the effect of obvious improvement.
- ⁇ -Glucan has the obvious improvement in all index under considering.
- ⁇ -Glucan in this invention can be used as the medicines, or the functional foods in form of capsule.
- Example 1 Effect of ⁇ -Gl ucan on growth of yeast and mould under the anaerobic conditions.
- the experimental liquid was vaccinated on SAVRO culture medium's surface, and cultured at 30°C for 3 ⁇ 5days to calculate the number of colony.
- sample suspension usually was vaccinated on the argar culture medium ' s surface and cultured at 35 °C for 20 hours to calculate the number of colony.
- sample was vaccinated on the BG LB (containing lactose) culture medium, and cultured at 35°C for 24 hours to decision existence of production of gas and product was vaccinated on the ENDO culture medium, and cultured for 12 hours to calculate the number of colony.
- BG LB containing lactose
- sample was vaccinated on the lactic acid bacteria's culture medium, and cultured at 35°C for 20 hours to calculate the number of yel low colony.
- Hexachloran by gas chromatography and coarse fibre & moisture by drying method was measured.
- the culture condition is 25 °C( ⁇ 2), culture time is 48 hours, nutrient source is sugar and mineral salt, and concentration of polysaccharide is 0.02%, experimental germ name is SACCHA RO YSES CEREVISIAE
- the polysaccharides such as carboxylethylglucan, schizopilan. starch, Cardran, Csantan, alginic acid have no effect on the biosynthesis of yeast, in the concentration of 0.02%.
- seasoning corresponding to the vegetable of l OOKg as stuffs of Kimchi.
- the polysaccharide, ⁇ -Glucan delaying the biosynthesis of yeast and mould under the anaerobic condition of 5g is added hereto and mixed equally, and then Kimchi was completed with these spices.
- seasoning include pulverized red pepper of 5 Kg, garlic of 300g, stone-leek of l OOg, ginger of 50g, salt of 50g, and salted fish of 500g.
- the above listed pices were mixed equally and kneaded with warm water and then used as seasoning.
- the composition of the above mentioned seasoning is not limited to above that and it could be modified according to taste of user.
- the vegetable After completion of Kimchi, the vegetable should be soaked in Kimchi ' s juice.
- the control was made without onlyP-Glucan by the same method.
- Kimchi has developed its flavour for 40days with keeping at 5 ⁇ I 0°C.
- Table 2 shows the influence in case that ⁇ -Glucan delaying the biosynthesis of yeast and mould under the anaerobic condition is added to the vegetable- fermented foodstuffs, Kimchi.
- ⁇ -Glucan 2 the control As seen in the Table 2, in Kimchi which ⁇ -Glucan is added in the seasoning, the biosynthesis yeast and mould is selectly delayed. And the biosynthesis of vitamin B l & B2 is accelerated quintuple and over. Also, the flavour of the kimchi is good, and unsoured term is extended, and decomposition is prevented.
- ⁇ -Glucan is administered by 0.25g each time, one hour before meal twice a day.
- Ariman "" TM is a trademark name of lipomanan extracted from Acetobacter SP, gram-negative bacterium.
- liver swel ling Pains in the liver region, indigestion, inertia, and loss of appetite, abdominal disorders, diarrhea, constipation, and hemorrhage were noticed as self conscious symptoms. Liver swel ling, spleen swelling, liver beating pain, sclera icterus, palm-rose hash, and dilation of the abdominal be in were noticed in the diagnostic symptom.
- Bil indices were observed in tests of bile pigment metaboism.
- Treating effects were judged by comparing the disappearance of clinical symptoms, the degree of improvement and the results of the tests before and after treatment.
- Table 1 shows results of comparison of changes in main self-conscious symptoms before and after treatment.
- the total rate of improvement in the experimental group was 92.0%, which was 69.4% improvement from the control group (p ⁇ 0.05). Changes in self-conscious symptoms
- Table 2 shows results of comparison of changes in objective symptoms before and after treatment.
- the serum albumin amount in the experimental group before the treatment was 6.8 ⁇ 0.2g/dl, while that in the control was 6.7 ⁇ 0.1g/dl.
- the post-treatment amounts of serum albumin in the experimental and control groups were 6.9 ⁇ 0.3g/dl and 6.9 ⁇ 0.2g/dl, respectively, whereas the pre and post treatment gap between the groups was different. It was likely to increase the amount of serum albumin.
- Table 5 shows the change in serum colloid reaction before and after treatment. Change in serum colloid reaction Table
- TIT distinctly decreases from 7.5 ⁇ 0.8 before treatment to 4.6 ⁇ 0.7 after treatment (PO.05).
- ZTT in the experimental group decreases from 16.7 ⁇ 0.6% before treatment to 12.5 ⁇ 0.7% after treatment The change in the control group was insignificant.
- Table 6 shows the change in transaminase activity before and after treatment.
- alkali phosphatase was 4.4 ⁇ 0.4 and 4.3 ⁇ 0.3 for both the experimental and control group.
- choiinesterase in the experimental group discovered an 3 increase from pre-treatment 786.1 ⁇ 21.6 to post-treatment 967.3 ⁇ 17.4. The control showed no significant change.
- Table 9 shows comparisons and observations of the changes in the scintigram of liver before and after treatment.
- Table 10 shows the comparative observations of changes in the test of peripheral blood before and after treatment.
- the number of white and red corpuscles of the experimental and control groups is from 4 I2.9 ⁇ 14.5 to 497.4 ⁇ I4.4 respectively after treatment compared with pretreatment and increased from 4.1 ⁇ 0.34 to 6.4 ⁇ 0.3.
- the number of the experimental groups thrombocytes sharply increased from pretreatment 1 1.4 ⁇ 0.12 ⁇ 10 4 /mm to 12.3 ⁇ 0.27x l0 4 /mm (p ⁇ 0.05).
- the negative test value of HBs Ag means lose, when the test value goes down to less than 64 times from over 128 times it means lowering.
- Table 1 1 shows the change, when there is no change in the test value fluctuating above 128 times.
- the change rate of the experimental group's HBs Ag test value is 48.2 percent, which is much higher than that in the control group, 25 percent.
- Table 12 shows comparative observations of the tests of immunity function before and after treatment.
- the rate of juvenility the lymphocyte in the experimental group was remarkably improved after treatment compared with pretreatment but where was no special change in the control group.
- the experimental group 50 percent of complement value has changed noticeably after treatment compared with pretreatment value was no distinct change in the control group.
- the change of two groups immune complexes has improved noticeably after treatment compared with pretreatment (p ⁇ 0.01 and p ⁇ 0.05 each).
- Table 13 shows the effects of two groups' treatment confirmed by the judgment standard.
- Table 14 shows the average treatment days of those patients who left hospital after favorable turn.
- Table 15 shows the results of two remote observations of 70 cases completely cared with ⁇ -glucan.
- Weight was measured once a week at noon by wearing a layer of undergarment (weight scale of l OOg sensitivity level passed through national authorization was used). Waist and hip measurements were taken with measuring tape around navel and the most prominent part around the hips while the subject person removed clothing, comfortably relaxed both arms and exhaled. AObservation method
- the target patients were fed 1 OOg cooked rice.
- Blood glucose level was measured by obtaining blood sample from the tip of finger when the subject person was in empty stomach in the morning as well as 1 hour and 2 hours after feeding cooked rice.
- Test for glucose tolerance was administered both before and after administering 0.2g of drug per day for 3 months, 6 months and 1 year. Blood glucose level was measured by obtaining blood sample from the tip of finger when the subject person was in empty stomach in the morning as well as 1 hour and 2 hours after feeding cooked rice (the same amount as above).
- Blood biochemical indices such as serum, cholesterol and triglyceride level, etc. were measured by using the automatic analyzer of Hitachi 912. After using serum and insulin automatic analyzer of Elecsys 2010, the HOMA-R (homeostasis model of assessment insulin resistance) was calculated with the following equation.
- HOMA-R FIxFG/22.5; FI: Fasting serum insulin ( ⁇ /ml)
- Hematological test was administered with automatic analyzer Sysmex XE-2100.
- ⁇ -Glucan produced continued effect to lower blood glucose level from 6 months after administration. However, there was no difference observed in the case of administering ArimanTM polysaccharides.
- the degree of weight reduction can be divided into the categories shown in Table 20.
- the rate of efficiency displayed by the experimental group with administration of ⁇ -Glucan was of 90% or higher.
- ⁇ -Glucan significantly lowered fasting serum insulin value and ⁇ - ⁇ index in type-2 diabetics after 6 months of treatment.
- ⁇ -Glucan produced proximately 80% of treatment effect on diabetes.
- ⁇ -Glucan was used as test material. Also, 72 ICR/JCL adult white rats and 130 mice were bred in the animal cage in Pyongyang Medical University were randomly used as experimental subjects with no specification in sex.
- Chronic liver poisoning was incurred by subcutaneously injecting 10% of carbon tetrachloride and O. I 2ml/ 10g of corn oil to the rats and 50% of carbon tetrachloride and 0.25ml/ 100g of corn oil to the mice, both through the dorsal area, once in three days and 10 injections per administration.
- Fat content in l iver tissue was calculated by deducting the remnant weight after extracting fat from the total liver weight.
- the poisoned control group (90.4 ⁇ 6.7) was distinctly higher than the normal control group (43.6 ⁇ 5.8), and experimental group to which the dosage of 20mg/kg was given was lower than the poisoned control group (pO.01).
- the toxic dose of carbon tetrachloride was injected into the white mice.
- the control group normal, poisoned
- Various doses of the drug (0.1 ml/1 Og, 40mg/kg, and 60mg/kg) were given to the experimental group for 30 days. Then, the galactose metabolic treatment function was evaluated on the 31 st day of the experiment.
- the level of blood sugar in the experimental group was 6 l .6 ⁇ 4mg/dl and 63.1 ⁇ 3.7mg/dl, respectively.
- the level in the experimental group decreased significantly compared to that in the poisoned control group (p ⁇ 0.01).
- the blood sugar level in the experiment group decreased close to that in the normal control group.
- mice 32 mice were divided into 4 groups of 8 rats.
- liver tissue was used to test the effect on the fat content of the liver.
- the index of fat content in the liver tissue (lg) was 39.7 ⁇ 1.8mg/g in the poisoned control group, which increased distinctly compared to that in the normal control group.
- the index of the BPB concentration in a blood serum of the poisoned control group was 3.54 ⁇ 0.25mg/%, which increased distinctly compared to that in the normal control group.
- the BPB concentrations of the blood serum were 3.14 ⁇ 0.26mg/%, 1.63 ⁇ 0.15mg/% and 1.53 ⁇ 0.01 mg/% depending on the dosage given, which are significantly lower than that in the poisoned control group (3.54 ⁇ 0.25mg /%). (pO.01)
- mice 30 white mice were divided into 3 groups of 10 mice.
- the result was evaluated by obtaining the number of the survived animals and died animals and compared them between the control and experimental groups in 72 hours after the injection of ammonium chloride.
- mice 12 white mice, 18 ⁇ 22g in weight, were divided into 4 groups of 3 mice. Each mouse was given with the drug at various dosages ( l OOmg/lOg, 500mg/10g, lOOOmg/lOg and 2000mg/10g). After 48 hours, no subject was found dead.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Use of β-glucan delaying the biosynthesis of yeast and mold under anaerobic condition for producing vegetable-fermented foodstuffs including functional health food, Kimchi, unrefined liquor and preventing and treating diseases including hepatitis, diabetes, obese and arteriosclerosis.
Description
The use of β-GIucan delaying the
biosynthesis of yeast and mold under anaerobic condition
Field of Invention
This invention relates to the use of β-glucan having the immune and hyperhepatia activity of the body. Background and purpose of Invention
The function of β-Glucan, the main component of mushroom polysaccharide is being watched and the research of its structure, mechanism of the action and its use has achieved the great progress, and some of them are widely disseminated in the field of medical treatment for the promotion of health. ( -fj fSi i¾—„ β-
4 4 , 1 i , 2 0 0 9 , 3 - 4 ) β-Glucan is a kind of functional polysaccharide from vegetable derivation and included in barley, black yeast, or mushroom and it is examined to decreasing the cholesterol content in the blood or restraining elevation of blood glucose value, treating of the adipositas, anticancer effectiveness, treating effectiveness of hepatic diseases. As the result, a lot of research data have been published that β-Glucan increases the immune function of human and have the treatment effectiveness to al lergic rhinitis and have anticancer effectiveness. |¾ , β- ? > Jo c tlfit t fi ifa t 4 4 , 1 1 , 2
0 0 9 , 1 4 — 1 5 ) With the exeception of the above documents, materials about the pharmaceutical effect of β-G lucan were mentioned in US Patent no. 5.576.015 and 5.504.079.
Many study have been alreadly made against the method to devide β-Gl ucan owing to its effect and disclosed in many documents (US 005599697A. US 005385832A etc.).
Recently, as the effect that imchi. the national diet in the DPR Korea has is verified in various points of view, the preparing method of Kimchi is variously developed and the filed of its use is more and more expanded.
WO2000003608 A l 20000127 disclosed a pulverized Kimchi seasoning composition and it's preparing method and WO2001084942 disclosed the preparing method of Kimchi with silkworm Dong-Chung-Ha-Cho. This Kimchi is beneficial to the health of the body owing to its containging Cordyceps mil itaris, has a good flavour. WO200 I 087078 A I 2001 1 122 disclosed white Kimchi containg opuntia, which is beneficial to the health of the body owing to its containing opuntia and has a peculiar flavour, thereby becoming a globalized food.
Like this, various methods to peculiarize a flavour of Kimchi and raise its nutritional physiological activity by adding the other materials having pharmacological activity in Kimchi are proposed.
This invention relates to the use of β-Glucan delaying the biosynthesis process of yeast and mold in anaerobic condition and provides the methods to apply β-Glucan to vegetable-fermented foodstuffs such as Kimchi.
I
Also, this invention provides the methods to apply β-Gl ucan delaying the biosynthesis process of yeast and mold under anaerobic condition to treatment of the disease such as hepatic diseases and adipositas.
Brief description of the invention
This invention mentions that β-Glucan delays selectively only the growth of yeast and mold in anaerobic condition and increases the biosynthesis of B | and B2 of yeast more than 5 times.
This invention discloses the method of using of β-Glucan in the fermented foodstuffs such as imchi and unrefined liquor. When making the vegetable-fermented foodstuffs such as Kimchi, 5g of β-Glucan can be mixed in its seasoning. With this usage, Kimchi was tasty and the period to be not sour was extended than comparison.
This invention describes the method of using of β-Glucan in treating of modern diseases such as adipositas and diabetes and hepatic disease.
The mentioned β-Gl ucan is injected oral ly by 0.5g.
To consider the effectiveness of treating the hepatic diseases, the activation of enzyme ""GPT", "GOT", ""ALP", '"CHE" as its experimental test indicator and BiL-exponent as the test relating to metabolism of the bile pigment has been observed. And the test of the periphery blood has indicates the counts of red cell, leukocyte, blood platelet, and for observing the functional and morphological changes of the liver, the dimensions of lobus hepatic sinister, lobus hepatic dexter, and spleen have been measured by the fluorescence detector of liver, and as the test of immune function, the weakening rate of lymph cell, CH50. lc has been tested. β-Glucan in indices related to all examination enumerated has the effect of obvious improvement. When the patients of diabetes and adipositas has been treated by administering with 0.25g of β-Glucan each time, one hour before breakfast and dinner twice a day. β-Glucan has the obvious improvement in all index under considering.
β-Glucan in this invention can be used as the medicines, or the functional foods in form of capsule.
Detailed Description of the Invention This invention is concretely described by the following examples.
[Example 1 ] Effect of β-Gl ucan on growth of yeast and mould under the anaerobic conditions.
I . Materials and method
For yeast and mould, the experimental liquid was vaccinated on SAVRO culture medium's surface, and cultured at 30°C for 3~5days to calculate the number of colony.
For the bacterium, sample suspension usually was vaccinated on the argar culture medium's surface and cultured at 35 °C for 20 hours to calculate the number of colony.
7
For the coli bacillus, sample was vaccinated on the BG LB (containing lactose) culture medium, and cultured at 35°C for 24 hours to decision existence of production of gas and product was vaccinated on the ENDO culture medium, and cultured for 12 hours to calculate the number of colony.
For the lactic acid bacteria, sample was vaccinated on the lactic acid bacteria's culture medium, and cultured at 35°C for 20 hours to calculate the number of yel low colony.
The crude protein by kjeldahl method, total acidity by titrimetry. and vitamin C & vitamin B l by fluorescent method was measured.
Vitamin B2 by AOAC. β-carotin & nitrous acid/nitrate by spectrophotometry, lead, cadmi um, natrium and kalium by atomic absorption method was measured.
Hexachloran by gas chromatography and coarse fibre & moisture by drying method was measured. Experiment on effect of β-Glucan on the biosynthesis of yeast under the anaerobic culture conditions was made in the different concentrations of sugar.
The culture condition is 25 °C(±2), culture time is 48 hours, nutrient source is sugar and mineral salt, and concentration of polysaccharide is 0.02%, experimental germ name is SACCHA RO YSES CEREVISIAE
2. Result
Table 1 shows results of the experiment on β-Glucan delaying the biosynthesis of yeast and mould under the anaerobic culture conditions.
Effect of β-Gl ucan on the biosynthesis of yeast Table I
It shows that growth of the yeast is delayed by β-Gl ucan delaying the biosynthesis of yeast and mould under the anaerobic culture conditions.
The polysaccharides such as carboxylethylglucan, schizopilan. starch, Cardran, Csantan, alginic acid have no effect on the biosynthesis of yeast, in the concentration of 0.02%.
[Example 2] Effect in case that β-G l ucan delaying the biosynthesis of yeast and mould under the anaerobic conditions was added to the vegetable- fermented foodstuffs. K imchi.
1 . Materia! and method
To make seasoning corresponding to the vegetable of l OOKg as stuffs of Kimchi. the polysaccharide, β-Glucan delaying the biosynthesis of yeast and mould under the anaerobic condition of 5g is added hereto and mixed equally, and then Kimchi was completed with these spices. Wherin, seasoning include pulverized red pepper of 5 Kg, garlic of 300g, stone-leek of l OOg, ginger of 50g, salt of 50g, and salted fish of 500g. The above listed pices were mixed equally and kneaded with warm water and then used as seasoning. The composition of the above mentioned seasoning is not limited to above that and it could be modified according to taste of user.
After completion of Kimchi, the vegetable should be soaked in Kimchi 's juice.
The control was made without onlyP-Glucan by the same method.
Kimchi has developed its flavour for 40days with keeping at 5~ I 0°C.
2. Result
Table 2 shows the influence in case that β-Glucan delaying the biosynthesis of yeast and mould under the anaerobic condition is added to the vegetable- fermented foodstuffs, Kimchi.
The effect on the microorganism of the vegetable- fermented foodstuffs, "Kimchi" of β-Giucan. Table 2
¾ 1 : β-Glucan 2: the control
As seen in the Table 2, in Kimchi which β-Glucan is added in the seasoning, the biosynthesis yeast and mould is selectly delayed. And the biosynthesis of vitamin B l & B2 is accelerated quintuple and over. Also, the flavour of the kimchi is good, and unsoured term is extended, and decomposition is prevented.
[Example 3] Effectiveness when β-Gl ucan under anaerobic condition is administered to hepatitis patients.
I . Material and method
β-Glucan is administered by 0.25g each time, one hour before meal twice a day. In control group, "Ariman"™ polysaccharide by 0.25g each time, one hour before meal twice a day. "Ariman""™ is a trademark name of lipomanan extracted from Acetobacter SP, gram-negative bacterium.
2. The observing items of treating effect
1 ) Clinical symptoms
Pains in the liver region, indigestion, inertia, and loss of appetite, abdominal disorders, diarrhea, constipation, and hemorrhage were noticed as self conscious symptoms. Liver swel ling, spleen swelling, liver beating pain, sclera icterus, palm-rose hash, and dilation of the abdominal be in were noticed in the diagnostic symptom.
2) Experimental test
® The level of enzyme activation was observed with the leverl of GPT, GOT. ALP, CHE.
© Bil indices were observed in tests of bile pigment metaboism.
© The number of erythrocytes, leucocytes, and blood platelets were observed.
® To observe the function of the liver and its morphological changes, the left and right lobe of the liver, and the size of the spleen were measured with Scintiinat-2.
© Test of the rete of lymphocyte juvenility. CH5U and 1C were carried out to observe immunity functions.
3) The judging criterion of treating effects
Treating effects were judged by comparing the disappearance of clinical symptoms, the degree of improvement and the results of the tests before and after treatment.
Favorable improvement: three or more self-conscious symptoms have disappeared, objective symptoms show improvement, and results of test are near normal.
No change: results of test show no improvement after the beginning of treatment, though some improvement was observed in the clinical symptoms.
Aggravation: the cl inical symptoms and results of test were aggravated.
The tests were carried once every 1 5 days and the effects before and after treatment were judged by
t-examination.
4) Remote observation judgment criterion
Remote observation was assessed by comparing clinical symptoms and results of tests during and after treatment in hospital.
Markedly good: clinical symptoms and results of tests remain unchanged for two years or more.
Good: results of tests remain un-changed, some self-conscious symptoms appear, depending on conditions.
Aggravation; pathological symptoms are noticed in clinical symptoms and results of test in two years after the hospital discharge.
5) Diagnostic criterion of chronic hepatitis
We followed the criteria of diagnosis of virus chronic hepatitis prescribed in volume 5, of complete book of prevention of infectious diseases.
GPI>35, GOT>140, TTT>4, ZTT>14, Alb<58%, GGT>25%
6) Diagnostic standard of progressive hepato-cirrhosis
Diagnostic standard of progressive hepato-cirrhosis referred to the information of document.
[ - The clinics of hepatic diseases, 21-119, 1991 , Kim Ha won,
- Encyclopedia of treating the hepatopathy, 25- 1 14, 1985, the Publishing House of Foreign Language,
- The Internal Medicine Book 12, 150-200, 1981 , the Publishing House of Science Encyclopedia, Kye
Sun Bom
3. The result
1) Changes in self-conscious symptoms
Table 1 shows results of comparison of changes in main self-conscious symptoms before and after treatment.
As shown in Table 1 , the rate of self-conscious symptoms in both groups before treatment was not distinct. After the treatment, all the indices of self-conscious symptoms in the experimental group considerably improved compared to those in the control group. The improvement of pains in the liver area, inertia, indigestion, and diarrhea was extraordinarily significant.
The total rate of improvement in the experimental group was 92.0%, which was 69.4% improvement from the control group (p<0.05).
Changes in self-conscious symptoms
*: P<0.05 P: comparison with control
2) Changes of objective symptoms
Table 2 shows results of comparison of changes in objective symptoms before and after treatment.
Change of objective symptoms Table 2
*: PO.05 P: comparison with control
As summarized in Table 2, the difference between the experimental and control groups in the rates of diagnostic symptoms was insignificant before the treatment. The rate of improvement of main diagnostic symptoms after treatment in the experimental group was higher than that in the control group in all indices.
The total improvement rate in the experimental group was 83.9%, 12.3% higher than that in the control group.
3) Changes in opinions of clinical experiment
Δ Change in the test opinion of protein metabolic function
© Change in serum protein amount
Change in serum albumin before and after the treatment is summarized in Table 3.
. Change in serum albumin amount Table 3
PI : Comparison with pre and post treatment; P2: Comparison with control
As shown in Table 3, the serum albumin amount in the experimental group before the treatment was 6.8±0.2g/dl, while that in the control was 6.7±0.1g/dl. The post-treatment amounts of serum albumin in the experimental and control groups were 6.9±0.3g/dl and 6.9±0.2g/dl, respectively, whereas the pre and post treatment gap between the groups was different. It was likely to increase the amount of serum albumin.
© Change in serum proteinogram
Change in serum albumin proteinogram before and after treatment in summarized in Table 4.
Change in serum albumin distribution Table 4
* P<0.05 P: Comparison with pre and post treatment, P': Comparison with control
As shown in Table 4, in the experimental group distinctly increases the albumin from 43.1±1.2% before treatment to 51.4±1.7% after treatment (p<0.05). The control group showed tendency to increase, but no marked difference. As far as γ-globulin is concerned, the experimental group experiences a spectacular fall from 34.7±1.5% before treatment to 26.6±1.4% after treatment. The control group had not an obvious change. ® Change in serum colloid reaction
Table 5 shows the change in serum colloid reaction before and after treatment.
Change in serum colloid reaction Table
* P <0.05 P: Comparison with pre and post treatment, P': Comparison with control
As shown in Table, in the experimental group, TIT distinctly decreases from 7.5±0.8 before treatment to 4.6±0.7 after treatment (PO.05). In the control group had not an obvious change. ZTT in the experimental group decreases from 16.7±0.6% before treatment to 12.5±0.7% after treatment The change in the control group was insignificant.
Δ Change in serum enzyme activity
Φ Change in transaminase activity
Table 6 shows the change in transaminase activity before and after treatment.
Change in the transaminase Table 6
***P<0.01 P: Comparison with pre and post treatment
P': Comparison with control
As seen in Table 6, in the experimental group and control group saw a fresh improvement of GPT and GOT after treatment as against before treatment (p>0.001 each). A comparative look at the change showed that the experimental group's value was much higher than the control group (p<0.05).
Change in alkali phosphatase and choiinesterase activation.
Table 7 shows the changes in alkali phosphatase and choiinesterase activation before and after treatment.
As seen in Table 7 alkali phosphatase was 4.4±0.4 and 4.3±0.3 for both the experimental and control group.
The level of alkali phosphatase in the experimental group fell to 2.1 ±0.2 after treatment (pO.OOl), but the control group did not see a meaningful gap. As for choiinesterase, in the experimental group discovered an
3 increase from pre-treatment 786.1 ±21.6 to post-treatment 967.3± 17.4. The control showed no significant change.
The change of acitivities of alkaliphosphatase and cholinesterase. Table 7
P: comparison between pre and post treatment
P': comparison with control group
Δ Change in serum icterus index
Change in serum icterus index before and after treatment is illustrated in Table 8.
Change in number of serum icterus Table 8
***P<0.001 P: comparison between pre and post treatment;
P': comparison with control group
As shown in Table 8, the serum icterus of both experimental and control groups were reduced remarkably in the indices after treatment compared to before treatment (pO.001).
The experimental group considerably improved compared to those in the control group (PO.05).
Δ Change in the liver scintigram
Table 9 shows comparisons and observations of the changes in the scintigram of liver before and after treatment.
Change in liver scintigram Table 9
P': Comparison with the control group
As clear shown in Table 9, the size of the experimental group's right portion of the liver and left of the liver, spleen after treatment compared with pretreatment (P<0.05, PO.01). The size of the control group's and left livers and spleen showed the trend toward improvement but the trend was not noticeable. There was nothing noticeable between the two groups
Δ Change in test of peripheral blood
Table 10 shows the comparative observations of changes in the test of peripheral blood before and after treatment.
P: Pretreatment comparison P': Comparison with control
As shown in the Table, the number of white and red corpuscles of the experimental and control groups is from 4 I2.9±14.5 to 497.4± I4.4 respectively after treatment compared with pretreatment and increased from 4.1±0.34 to 6.4±0.3. The number of the experimental groups thrombocytes sharply increased from pretreatment 1 1.4±0.12χ 104 /mm to 12.3±0.27x l04 /mm (p<0.05). There was a considerable difference between the experimental group and control group in the change of the number of white corpuscles and thrombocytes.
A Change in the test value of HBs Ag
The negative test value of HBs Ag means lose, when the test value goes down to less than 64 times from over 128 times it means lowering. Table 1 1 shows the change, when there is no change in the test value fluctuating above 128 times.
As shown in Table 1 1 , the change rate of the experimental group's HBs Ag test value is 48.2 percent, which is much higher than that in the control group, 25 percent.
*P<0.05 P: Comparison with the contol group
® Change in the test value of immunity function
Table 12 shows comparative observations of the tests of immunity function before and after treatment.
As shown from Table 12, the rate of juvenility the lymphocyte in the experimental group was remarkably improved after treatment compared with pretreatment but where was no special change in the control group. The experimental group 50 percent of complement value has changed noticeably after treatment compared with pretreatment value was no distinct change in the control group. The change of two groups immune complexes has improved noticeably after treatment compared with pretreatment (p<0.01 and p<0.05 each).
The test value changes of immune function Table 12
*P<0.05 **P<0.01 P: Pretreatment comparison
4) Overall results of treatment
® The treatment results
Table 13 shows the effects of two groups' treatment confirmed by the judgment standard.
Overall treatment results Table 13
As shown in the Table, the effect rate of the experimental group was noticeably higher.
© Average treatment days
Table 14 shows the average treatment days of those patients who left hospital after favorable turn.
As shown in the Table, the average treatment days in the experimental group are 32.9±1.9 days, which shorter than those in the control group, which were 43.5±2.6. (P<0.05)
The average number of treatment days Table 14
© Remote observation results
Table 15 shows the results of two remote observations of 70 cases completely cared with β-glucan.
Remote observation results Table 15
As Table 15 shows, four of the experimental groups 70 cases (5.7 %) worsened. Among the four cases, one case became active chronic hepatitis and three cases early fattening the unprogressive hepatocirrhosis. Four of the control group 16 cases (25 %) worsened and three cases became active and one case early fattening the unprogressive hepatocirrhosis.
[Example 4] effect of β-Glucan for diabetics
Δ Materials and method
Φ Materials
The method of orally administering β-Glucan one hour before breakfast/dinner twice a day by 0.5g each time. For the control group, administration of Ariman™ polysaccharides before meal twice a day by 0.25g each time.
Analysis facility and tools
Experiment and result processing was administered by using the internationally certified automatic analyzer (Hitachi 912, Japan), automatic analyzer (Elecsys 2010, Japan), automatic analyzer (Sysmex XE-2100, Japan), body composition analyzer (In Body 3.0), computer (HP, Pentium 4) and electronic scale (CAS, accuracy rate of 50g).
(D Measurement on human body and observation method
Δ Measurement indices
Weight was measured once a week at noon by wearing a layer of undergarment (weight scale of l OOg sensitivity level passed through national authorization was used). Waist and hip measurements were taken with measuring tape around navel and the most prominent part around the hips while the subject person removed clothing, comfortably relaxed both arms and exhaled.
AObservation method
- For subjective symptoms, the volume and frequency of urination, feeling of heaviness and breathlessness were the main symptoms to observe. In addition, target patients were observed 2~3 times a week for the conditions, such as feeling of unpleasantness in the heart, headache, heaviness in the head, feeling of soreness in the limps and thirst, etc. The results were checked as either (+) or (-) in the result sheet. New symptoms to occur in the course of treatment were recorded in the record chart. For treatment, supervised administration of drug was administered 1~2 times. With focus placed on onsite treatment, it was ensured to produce no changes in the level of diet and exercise in the entire course of treatment.
- Experimental test
o Test for post-prandial blood glucose level
After administering drug to type-2 diabetics, the target patients were fed 1 OOg cooked rice. Blood glucose level was measured by obtaining blood sample from the tip of finger when the subject person was in empty stomach in the morning as well as 1 hour and 2 hours after feeding cooked rice.
o Test for glucose tolerance
Test for glucose tolerance was administered both before and after administering 0.2g of drug per day for 3 months, 6 months and 1 year. Blood glucose level was measured by obtaining blood sample from the tip of finger when the subject person was in empty stomach in the morning as well as 1 hour and 2 hours after feeding cooked rice (the same amount as above).
o Blood analysis
Blood biochemical indices, such as serum, cholesterol and triglyceride level, etc. were measured by using the automatic analyzer of Hitachi 912. After using serum and insulin automatic analyzer of Elecsys 2010, the HOMA-R (homeostasis model of assessment insulin resistance) was calculated with the following equation.
HOMA-R=FIxFG/22.5; FI: Fasting serum insulin (μυ/ml)
FG: Fasting glucose level (mg/dl)
Hematological test was administered with automatic analyzer Sysmex XE-2100.
- Processing of results
o According to the value of blood glucose obtained after loading of glucose, the area below the curve of blood glucose and its increase were calculated with the following equation.
Area below the curve of blood glucose: S(area of blood glucose) = 1/4 (a+ab+c);(mg/dl h)
Increase in the area below the curve of blood glucose:
o 2s (area of blood glucose) =t [1/a (a+ab+c)-a] ;( mg/dl-h)
t: Time of the last blood sample collection (h)
a: Blood glucose level at the beginning of experiment (in empty stomach) (mg/dl)
b: Blood glucose level at t/2 (mg/dl)
c: Blood glucose level at t (mg/dl)
@ Results of treatment and bases of observation
Bases of evaluation per weight were categorized as the following in accordance with the degree of weight reduction and improvement of the condition.
Significant improvement: Reduction of weight by 2.0kg or more and simultaneous reduction of waist measurement was achieved in the course of treatment. Significant improvement was achieved in the subjective conditions.
Improvement: Reduction of weight by 1.0kg ~1.9kg and simultaneous reduction of waist measurement were achieved in the course of treatment. Relative improvement was achieved in the subjective conditions.
No change: There has been no change experienced in the weight and waist measurement during the course of treatment (± 1.0kg or less)
Results of experiment were calculated in computer (HP, Pentium 4) with ±SD. Also, significance level was measured with t-test method.
2. Results
1) Effect in obesity treatment
Changes in weight and blood serum composition in the obese.
After 7-day stabilization period, cross-test was administered by using β-Glucan and Ariman™ polysaccharides for the period of 6 months each. The result indicated changes in weight as shown in Table 16.
Changes in weight of the obese Table 16
Compared to the control group *P<0.05 n=59
As shown in the Table, average increased by 7.16kg among the obese in the 6-month control period (administration of Ariman™ polysaccharides). However, during the 6-month experimental period (administration of β-Glucan), the average weight increased by 0.44kg. In other words, β-Glucan decreased the average weight of the obese by 6.71 kg during the period of 6 months.
Blood biochemical indices and blood pressure during the period of experiment were as shown in Table 17.
Blood biochemical indices of the obese administered with compound pharmaceuticals Table 17(n=59)
With the exception of cholesterol level increased during stabilization period, there was no difference found between control and experimental groups in terms of triglyceride, HDL-cholesterol level, blood glucose level and GOT/GPT level.
i
J There was no difference, either, in systolic pressure and diastolic pressure.
Changes in weight and serum composition of the obese
j Δ Effect exerted on post-prandial blood glucose level
j Postprandial blood glucose level and increase in blood glucose level were as shown in Table 18.
I Post-prandial blood glucose level and increase in blood glucose level Table 18
* p<0.05 Significant difference by comparison, n=23
Conditions of experiment: After 2 days of stabilization and fasting of 12 hours, target people were fed bread
made with flour (lOOg flour). After administering the pharmaceutical for 6 months, blood sample was obtained from the tip of finger before feeding and both 1 and 2 hours after feeding to analyze blood glucose level.
As shown in the Table, β-Glucan produced continued effect to lower blood glucose level from 6 months after administration. However, there was no difference observed in the case of administering Ariman™ polysaccharides.
Δ Effect on weight
Weight reduction was found as shown in Table 19.
.Change in weight per month in the obese (kg) Table 19
***p<0.001, **p<0.01 significant difference from the control group, n=38
The degree of weight reduction can be divided into the categories shown in Table 20.
n=38
As shown in the Table, average weight reduction occurred from the 4* month after administration of β-Glucan. The weight reduced by 6.1 kg after 8 months of administration.
Changes in weight, BM1, waist measurement and hip measurement are as shown in Table 22.
**p<0.001, ***p<0.001 , n=38
After administration of β-Glucan, distinctive reduction in BMI and weight was observed.
Δ Effect on clinical symptoms
Subjective symptoms of the target people changed after administration of β-Glucan as shown in Table 23.
As shown in the Table, the major symptoms of breathlessness and feeling of heaviness experienced by target patients significantly decreased. In other symptoms, improvement of 60% or more was achieved in the conditions.
Changes in subjective symptoms (n=38) Table 23
Δ Effect on blood biochemical indices
Blood biochemical indices of the target people administered with β-Glucan and Ariman polysaccharides for 6 months are as shown in Table 24.
As shown in the Table, β-Glucan significantly lowered serum fat level, blood glucose level, serum cholesterol level and uric acid content in the obese compared to before administration. It also significantly improved liver function indices, such as GGT, GOT and GPT. However, there were no marked changes observed in blood biochemical indices in the control group with administration of Ariman™ polysaccharides.
Blood biochemical indices of the obese (n=38) Table 24
Compared to before experiment *p<0.05, **p<0.01 , cip<0.1
Δ Effect of the pharmaceutical on changing of physical composition
Results of physical composition analysis measured on the target people before and after administration of pharma-ceuticals for 6 months are as shown in Table 25.
As shown in the Table, the experimental group with β-Glucan administration displayed significant
reduction in body and increase in muscle mass and protein content after experiment. However, there was no marked difference found in the control group.
Change in physical composition of the targets of clinical experiment after administration Table 25
Compared to before experiment
(D Overall result of treatment
In summary, the obesity prevention effects of the pharmaceuticals are as shown in Table 27.
Overall treatment result (rate of efficiency) Table 27
As shown in the Table, the rate of efficiency displayed by the experimental group with administration of β-Glucan was of 90% or higher.
2) Effect on diabetes treatment
© Effect on glucose metabolism indices of type-2 diabetics according to the period of administration Δ Change in fasting glucose level and protein glycation index
Fasting blood glucose level and protein glycation values measured on type-2 diabetics administered with each pharmaceutical for 6 months are as shown in Table 28.
As shown in the Table, β-Glucan significantly lowered the fasting blood glucose level and protein glycation indices in type-2 diabetics in the 4th and 6th month of the treatment
Change in glucose metabolism indices of type-2 diabetics Table 28
Significant difference compared to before treatment *p<0.05, **p<0.01
Δ Effect on serum insulin and insulin resistance
Fasting serum insulin values measured on patients as of the above are shown in Table 29.
Significant difference compared to before treatment *p<0.05
As shown in the Table, β-Glucan significantly lowered fasting serum insulin value and ΗΟΜΑ-γ index in type-2 diabetics after 6 months of treatment.
(2) Effect on clinical symptoms of type-2 diabetics
The results of observing changes in subjective symptoms experienced by some patients after intake of β-Glucan for 6 months are shown in Table 30.
Changes in subjective symptoms after intake of β-Glucan Table 30
As shown in the Table, the typical subjective symptoms of the diabetics, such as lethargy, thirst and large volume of urine, were significantly reduced after treatment.
© Effect on serum lipid of type-2 diabetics
Changes in the level in serum lipid of type-2 diabetics after 6-month administration of β-Glucan were observed. As shown in Table 3 1 , triglyceride and cholesterol content in serum significantly decreased.
Effect on serum l i id of obese-t e diabetics Table 3 1
( ) rate of decrease compared to before treatment, significant difference compared to before treatment, **P<0.0 l . ** *P<0.00 l
@ Evaluation of treatment efficiency
Effect of β-Glucan on treatment of diabetes is evaluated as shown in Table 32.
As shown in the Table, β-Glucan produced proximately 80% of treatment effect on diabetes.
Improvement effect on diabetes by β-Glucan Table 32
[example 5] Toxicity experiment of β-G l ucan delaying the biosynthesis of yeast and mold under anaerobic condition
I . Materials and method
1 ) Materials
β-Glucan was used as test material. Also, 72 ICR/JCL adult white rats and 130 mice were bred in the animal cage in Pyongyang Medical University were randomly used as experimental subjects with no specification in sex.
2) Method
© Creating a chronic liver poisoning model
Chronic liver poisoning was incurred by subcutaneously injecting 10% of carbon tetrachloride and O. I 2ml/ 10g of corn oil to the rats and 50% of carbon tetrachloride and 0.25ml/ 100g of corn oil to the mice, both through the dorsal area, once in three days and 10 injections per administration.
Measurement and Method
- The effect on the activity of serum transaminase
For the purpose of testing the effect of the experimental drug to the liver function in chronic hepatitis intoxication, at the same time of initiation of toxication. city water may be administered at the amount of I .Om/l Og in control(normal control, toxication control)group and the polysaccharide which delays the biosynthesis of the yeast and mold under the anaerobic condition in experimental group may be administrated at the different dosage once daily for 30 days in test group. Experimental animals were beheaded on the 3 1 st day from the toxication, gathered the blood and measured the GPT and GOT level by Lightman-Prangkel method.
- The effect on fat content in the l iver tissue
The toxic dose of carbon tetrachloride was injected into the white rates. At the same time, the control group (normal, poisoned) was given with tap water at a dose of 0. I ml/ I OOg. Various doses of drug were given to experimental group once a day for 30 days. The animals were instantly sacrificed through cervical dissection on the 3 1 s' day of the experiment. Final ly, the liver was removed and completely desiccated in a hot-air drier for 24 hours.
The desiccated liver was grinded into fine pieces with a mortar and I g of the liver powder was placed into a soxhiet device to extract fat from the water. After fat was completely extracted by using ether solution, and the powder was dried and then weighted.
Fat content in l iver tissue was calculated by deducting the remnant weight after extracting fat from the total liver weight.
- The effect on pigment degradation function of l iver
The toxic dose of carbon tetrachloride was injected into the white rats. At the same time, the control group (normal, poisoned) was given with tap water at a dose of 0. I ml/ I OOg. Various doses of drug were given to experimental group once a day for 30 days. 0. I ml/ I OOg of 2% bromphenol (BPB) was injected through tail vein. After 20 minutes blood form each animal was collected through cervical dissection. The concentration of BPB in the blood serum was measured by colorimetric titration.
- The effect on the detoxification of white rats" l iver
In the group of white mice, 0. 1 ml/ 1 Og of tap water was given to the control group and various doses of drug were given to the experimental group for 10 days. The animals, then, were treated with LD50 ( 160mg/kg) of ammonium chloride through the thoracic subcutaneous injection.
After 72 hours later, the number of the survived animals and died animals was obtained and compared between the compared and experimental groups.
2. Results
(T) The effect on the activity of serum Iransaminase
56 white mice were divided into 7 groups of 8 mice.
The result of the experiment was evaluated by comparing the indexes of GPT and GOT, measured through Light-Prankel method, in the blood serum.
The results were as follows.
As shown in the above Table, the activity of serum GOT in the poisoned control group (87.6±4.3) was significantly higher than that in the normal control group (26.9±2.1 ).
The serum GPT activity in the experimental group to which the dosage of 20mg/kg was given, was significantly lower than those in the poisoned control group (p<0.01 ).
The effect of drug on the serum transaminase activity Table 33
* p<0.01
Regarding the GOT activity, the poisoned control group (90.4±6.7) was distinctly higher than the normal control group (43.6±5.8), and experimental group to which the dosage of 20mg/kg was given was lower than the poisoned control group (pO.01).
The effect on galactose metabolic function
32 white mice were divided into 4 groups of 8 mice.
The toxic dose of carbon tetrachloride was injected into the white mice. At the same time, the control group (normal, poisoned) was given with tap water. Various doses of the drug (0.1 ml/1 Og, 40mg/kg, and 60mg/kg) were given to the experimental group for 30 days. Then, the galactose metabolic treatment function was evaluated on the 31st day of the experiment.
The level of blood sugar was obtained 30 minutes before and 30 minutes after giving galactose and the difference was compared between the control group and experimental group.
The res ults of experiment were as Table 34.
As seen in the above Table 34, the level of blood sugar in the poisoned control group (82.7±5.1mg%) distinctly increased compared to that in the normal control group (59.2±2.91).
The effect of drug on the galactose metabolic function of white mice Table 34
* pO.01
The level of blood sugar in the experimental group, to which 40mg/kg and 60mg/kg of drugs were given, was 6 l .6±4mg/dl and 63.1±3.7mg/dl, respectively. In addition, the level in the experimental group decreased significantly compared to that in the poisoned control group (p<0.01). The blood sugar level in the experiment group decreased close to that in the normal control group.
The results indicate the drug acted positively on the sugar metabolic function of the liver of rats.
The effect on fat content in liver tissue
32 mice were divided into 4 groups of 8 rats.
The toxic dose of carbon tetrachloride was injected into the white rates. At the same time, the control group (normal, poisoned) was given with tap water at a dose of l .Oml/lOOg. Various doses of drugs were given to experimental group once a day for 30 days. Then, the effect on the fat content of the liver was evaluated on the 3151 day of the experiment.
lg of liver tissue was used to test the effect on the fat content of the liver.
The results of test were as follows.
The effect of drug on the fat content in liver tissue of rats Table 35
*p<0.0
As shown in Table 35, the index of fat content in the liver tissue (lg) was 39.7± 1.8mg/g in the poisoned control group, which increased distinctly compared to that in the normal control group.
In the experimental group, the fat contents in the liver tissue were 26.2±1.8mg/g and 25.2±1.8mg/g, which decreased distinctly compared to that in the poisoned control group.
The result indicates the drug acted positively on the fat metabolic function of the liver of rats.
(4) Effect on pigment degradation function of liver
40 rats were divided into 5 groups of 8 rats.
The toxic dose of carbon tetrachloride was injected into the white rates. At the same time, the control group (normal, poisoned) was given with tap water at a dose of l .Oml/lOOg. 40mg kg, 60mg/kg and 80mg/kg of the drug were given to the experimental group once a day for 30 days.
Then, the effect on the pigment degradation function of the liver was observed on the 31 a day of the experiment.
The result was evaluated by comparing the BPB concentration in a blood serum 20 minutes after BPB injection between the control and experimental groups.
The results of test were as follows.
As shown in Table 5, the index of the BPB concentration in a blood serum of the poisoned control group was 3.54±0.25mg/%, which increased distinctly compared to that in the normal control group.
In the experimental group, the BPB concentrations of the blood serum were 3.14±0.26mg/%, 1.63±0.15mg/% and 1.53±0.01 mg/% depending on the dosage given, which are significantly lower than that in the poisoned control group (3.54±0.25mg /%). (pO.01)
The effect on the function of secreting liver pigment Table 36
*p<0.01
The result indicates the drug enhances the pigment degradation function of the rats' liver.
(D Effect on the detoxification of liver
30 white mice were divided into 3 groups of 10 mice.
The result was evaluated by obtaining the number of the survived animals and died animals and compared them between the control and experimental groups in 72 hours after the injection of ammonium chloride.
As seen in Table 37, in the experimental group treated with 60mg/kg and 80mg/kg of the drug, the dead animals were 4 (40%) and 3 (30%) respectively, which were significantly lower than that of the control group [6(60%)]. The result indicates the drug enhances the detoxification function of the liver of rats.
The effect on the detoxification of white rats' liver Table 37
(D Acute toxicity experiment
12 white mice, 18~22g in weight, were divided into 4 groups of 3 mice. Each mouse was given with the drug at various dosages ( l OOmg/lOg, 500mg/10g, lOOOmg/lOg and 2000mg/10g). After 48 hours, no subject was found dead.
In addition, no significant change in hair and behavioural movement of the white mice was identifiable after treated with the drug.
[Example 6] Clinical safety of β-Glucan
The quantity 5 times larger than that of the general administration was given to 24 healthy individuals for 15 days. Subjective symptoms and results of observation are as shown in Table 38.
As shown in the Table, there was no change in healthy people's subjective symptoms even after large quantity of drug administration. Although some experienced increase in the volume of urine, this conditions disappeared within 2~3 days.
In some cases, there were positive results of achieving improvement in terms of watery feces and constipation.
Changes in subjective symptoms after administration of acute drug (M±SD) Table 38
Also, as the result of observing hematological test results both before and after drug administration, there was no significant change identified in all of the indices (Table 39)
Changes in blood indices after administration of acute drug Table 39
As shown in Table, there were no changes observed between before and after drug administration in test indices of hematosis, such as the percentages of red blood corpuscles and leucocytes.
Changes in blood biochemical indices after administration of acute drug Table40
As shown in Table 40, there were no changes observed in blood biochemical indices after administration of acute drug, such as in indices for liver function (GOT, GPT, BILT, GGT, LDH), indices for kidney function (CREA, UREA) and indices for protein metabolism (ALB, TP, CHE).
Prior to entering the clinical phase, to evaluate the safety of β-Glucan delaying the biosynthesis of yeast and mold under anaerobic condition(standard 0- 1433-2001 ) the quantity 5 times larger than that of the general administration was given to 24 healthy individuals for 15 days.
As shown in the Table 38. there were no changes in biochemical indices and subjective symptoms.
After administration, there would be found the trend of improvement in property of stool. These result shows that this formulation gives affirmative effect to the function of digestive system.
Also, since indices such as indices of liver function and renal function were within normal range, toxicity of the formulation was not regarded.
Claims
I . The use of β-Glucan delaying the biosynthesis of yeast and mold under anaerobic condition for producing of vegetable-fermented foodstuffs, wherein the vegetable-fermented foodstuffs including functional health food, Kimchi and unrefined liquor.
2. The use according to Claim 1. wherein 5g of β-Glucan is mixed in seasoning corresponding to 100kg of vegetable.
3. The use of β-Glucan in prevention and treatment of diseases, wherein the diseases including the hepatitis, type-2 diabetes and obese.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KP70710 | 2010-10-23 | ||
KPKP-10-707 | 2010-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012053667A1 true WO2012053667A1 (en) | 2012-04-26 |
Family
ID=45975366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KP2011/000023 WO2012053667A1 (en) | 2010-10-23 | 2011-04-02 | USE OF β-GLUCAN DELAYING THE BIOSYNTHESIS OF YEAST AND MOLD UNDER ANAEROBIC CONDITION |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012053667A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160209425A1 (en) * | 2015-01-16 | 2016-07-21 | New York University | Use of dectin-1 activators for treatment of liver disorders |
CN106579115A (en) * | 2016-12-02 | 2017-04-26 | 华南协同创新研究院 | Preparation method and application of glucan fruit and vegetable enzymes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1151839A (en) * | 1996-09-27 | 1997-06-18 | 阜新市天然食品饮料厂 | Pickled vegetable produced by industrial salt-less fermentation and its prepn process |
WO1998050398A1 (en) * | 1997-05-07 | 1998-11-12 | Rutgers, The State University Of New Jersey | Improved beta-glucan and methods of use |
CN1593205A (en) * | 2004-07-08 | 2005-03-16 | 黄仁洙 | Chitin pickled vegetable and its preparation method |
CN101584361A (en) * | 2008-05-19 | 2009-11-25 | 株式会社金湖化成 | Chitosan powder for salting, salting object using the chitosan powder and pickled vegetable made by using chitosan powder |
-
2011
- 2011-04-02 WO PCT/KP2011/000023 patent/WO2012053667A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1151839A (en) * | 1996-09-27 | 1997-06-18 | 阜新市天然食品饮料厂 | Pickled vegetable produced by industrial salt-less fermentation and its prepn process |
WO1998050398A1 (en) * | 1997-05-07 | 1998-11-12 | Rutgers, The State University Of New Jersey | Improved beta-glucan and methods of use |
CN1593205A (en) * | 2004-07-08 | 2005-03-16 | 黄仁洙 | Chitin pickled vegetable and its preparation method |
CN101584361A (en) * | 2008-05-19 | 2009-11-25 | 株式会社金湖化成 | Chitosan powder for salting, salting object using the chitosan powder and pickled vegetable made by using chitosan powder |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160209425A1 (en) * | 2015-01-16 | 2016-07-21 | New York University | Use of dectin-1 activators for treatment of liver disorders |
CN106579115A (en) * | 2016-12-02 | 2017-04-26 | 华南协同创新研究院 | Preparation method and application of glucan fruit and vegetable enzymes |
CN106579115B (en) * | 2016-12-02 | 2020-08-25 | 华南协同创新研究院 | Preparation method and application of glucan fruit and vegetable enzyme |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kochhar et al. | Effect of supplementation of traditional medicinal plants on blood glucose in non–insulin-dependent diabetics: A pilot study | |
JP2020172523A (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
CN103829140A (en) | Cereal powder with functions of losing weight and reducing blood sugar | |
CN105079089A (en) | Preparation method of kudzuvine root and bitter gourd health-care food assisting in reducing blood glucose | |
CN104857088A (en) | Preparation method of mulberry leaf compound capsule for lowering blood glucose in assistant manner | |
CN101422465A (en) | Use of ursolic acid and plant extract containing the same | |
CN102526478A (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
CN105616958A (en) | Blood sugar decreasing composition, blood sugar decreasing health-care food and preparing method and application of blood sugar decreasing health-care food | |
CN101356975B (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
CN104661680B (en) | Compound and its influence to appetite control and insulin sensitivity | |
CN105725187B (en) | A kind of hypoglycemic composition and its purposes for being used to prepare food and health food | |
CN107343658A (en) | A kind of antifatigue SOD oyster peptides complex capsule and preparation method thereof | |
JP5344494B2 (en) | Lipid metabolism improving agent, functional food, food additive, antioxidant, medicine, arteriosclerosis preventive / improving agent, cosmetics, and method for producing lipid metabolism improving agent | |
CN112971154A (en) | Solid mixture rich in water-soluble dietary fibers and alpha-amylase inhibitor, and preparation method and application thereof | |
El-Kholie et al. | Anti Diabetic Effect Of Oats Flour On Streptozotocin-Induced Diabetic Rats | |
JP2019210269A (en) | Composition for treating diabetic disease | |
WO2012053667A1 (en) | USE OF β-GLUCAN DELAYING THE BIOSYNTHESIS OF YEAST AND MOLD UNDER ANAEROBIC CONDITION | |
CN102014944B (en) | Pharmaceutical composition using herbal extract for prevention and treatment of obesity and metabolic disorders | |
Okon et al. | Effect of ethanolic extracts of Persea americana seed and Zea mays silk on blood glucose levels, body and organ weights of alloxan-induced hyperglycemic albino wistar rats | |
CN1901927A (en) | Alpha-glucosidase activity inhibitor | |
CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
Lok et al. | Effects of polypeptide-k supplemented soft bun on blood glucose level in healthy adults | |
WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human | |
JP2018197220A (en) | Composition for improving metabolic syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11834500 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A, DATED 01-08-2013) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11834500 Country of ref document: EP Kind code of ref document: A1 |